A 52-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough (CALM-1)
view all Clinical Trials
Overview
This is a randomized, double-blind, placebo-controlled, parallel-arm, Phase 3 study of BLU-5937 in participants with Refractory Chronic Cough (RCC).
Contact
For more information about this trial or to inquire about eligibility, email [email protected] or call 215-707-1359.